| pubmed-article:8998181 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0023418 | lld:lifeskim |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0085112 | lld:lifeskim |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0028948 | lld:lifeskim |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:8998181 | lifeskim:mentions | umls-concept:C0031525 | lld:lifeskim |
| pubmed-article:8998181 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:8998181 | pubmed:dateCreated | 1997-2-4 | lld:pubmed |
| pubmed-article:8998181 | pubmed:abstractText | Philadelphia cells are human chronic myelogenous leukemia (CML) cells that contain the BCR/ABL oncogene (a fusion of the BCR and ABL genes). Selective eradication of these cells in vitro can be achieved by combined treatment with antisense phosphorothioate oligodeoxynucleotides ([S]ODNs) specifically targeted to this oncogene (bcr/abl [S]ODNs) and a suboptimal (for use as a single agent) dose of mafosfamide (the in vitro active form of cyclophosphamide). | lld:pubmed |
| pubmed-article:8998181 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8998181 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8998181 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8998181 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8998181 | pubmed:issn | 0027-8874 | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:KawiakJJ | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:CalabrettaBB | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:ChristensenLL | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:MajewskaEE | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:IozzoR VRV | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:HoserGG | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:PerrottaLL | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:SkorskiTT | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:Nieborowska-S... | lld:pubmed |
| pubmed-article:8998181 | pubmed:author | pubmed-author:WlodarskaHH | lld:pubmed |
| pubmed-article:8998181 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8998181 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8998181 | pubmed:volume | 89 | lld:pubmed |
| pubmed-article:8998181 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8998181 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8998181 | pubmed:pagination | 124-33 | lld:pubmed |
| pubmed-article:8998181 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:meshHeading | pubmed-meshheading:8998181-... | lld:pubmed |
| pubmed-article:8998181 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:8998181 | pubmed:articleTitle | Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides. | lld:pubmed |
| pubmed-article:8998181 | pubmed:affiliation | Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University, Philadelphia, PA 19107, USA. | lld:pubmed |
| pubmed-article:8998181 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8998181 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8998181 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8998181 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8998181 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8998181 | lld:pubmed |
